Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.

  title={Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.},
  author={Carole A Reeve and John S. Whitehall and Petra Gertraud Buettner and Robert Norton and David M Reeve and Fleur Francis},
  journal={Journal of paediatrics and child health},
  volume={42 5},
BACKGROUND A monoclonal antibody, palivizumab, directed against respiratory syncytial virus (RSV) has been shown to decrease hospitalisation rates. Because of its expense, the cost-effectiveness of this agent should be determined for high-risk groups. AIM To determine characteristics of RSV infection in Townsville and the economic feasibility of palivizumab immunoprophylaxis in high-risk groups. METHODS Cases of RSV-positive bronchiolitis were retrospectively identified. Cases were grouped… CONTINUE READING